Achieve Life Sciences Inc (ACHV) - News Archive

Breakthrough in Smoking Cessation: Achieve Life Sciences Secures FDA s National Priority Voucher Seattle, WA - October 2023 - In a landmark development, Achieve Life Sciences has been granted the FDA Commissioner s Nati...

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, significantly affecting the lives of millions of Americans. Smoking is the primary risk factor for developing COPD, yet many pa...

Achieve Life Sciences Partners with Omnicom for Innovative Launch of New Nicotine Dependence Treatment Achieve Life Sciences, a prominent company specializing in the development of therapies for nicotine addiction, unve...

In recent weeks, Achieve Life Sciences Inc. has garnered attention following the publication of its Phase 3 ORCA-3 trial results on cytisinicline, a potential new tool for smoking cessation. The findings, published in J...

In a dynamic move poised to bolster its commercial strategy, Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company renowned for its innovative approach to nicotine dependence treatment, has ann...

In a significant advancement for tobacco harm reduction strategies, Achieve Life Sciences Inc. recently announced the completion of enrollment in its ORCA-OL clinical trial, a pivotal study exploring the efficacy of its...

As public health officials continue to grapple with the rising tide of nicotine dependence linked to electronic cigarettes and vaping, emerging therapies are vital in addressing this growing epidemic. In this context, A...

Achieve Life Sciences Secures $20M Loan Refinancing with Silicon Valley Bank, Extending Maturity Date to 2027Achieve Life Sciences, a prominent late-stage pharmaceutical company specializing in smoking cessation and nic...

Seattle and Vancouver, British Columbia - Achieve Life Sciences, Inc. (Nasdaq: ACHV), a renowned late-stage pharmaceutical firm dedicated to the worldwide development and commercialization of cytisinicline for smoking c...

Long-Term Safety Evaluation of Cytisinicline for Smoking Cessation: Initiation of the ORCA-OL Clinical Trial Achieve Life Sciences has launched the ORCA-OL clinical trial to evaluate the long-term safety of cytisiniclin...

On May 17, 2024, Achieve Life Sciences, a leading pharmaceutical firm focused on global cytisinicline development for smoking cessation and nicotine addiction, revealed the findings from the Phase 2 ORCA-V1 vaping cessa...

In a significant development, Achieve Life Sciences recently announced that it has successfully reached an agreement with the U.S. Food and Drug Administration (FDA) regarding the requirements for long-term exposure dat...